# A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder

> **NCT00921063** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 222 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** PD 0332334
- **DRUG:** PD 0332334
- **DRUG:** placebo
- **DRUG:** Alprazolam extended release

## Key facts

- **NCT ID:** NCT00921063
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2010-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00921063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00921063, "A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00921063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*